AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential...
CoronaVac® generates good immune memory after the second dose. Third dose of CoronaVac® induces strong immune response. No serious adverse reactions reported
The state registry notes that the trials will last until late 2026 and will involve 360 patients. The vaccine will be administered via an intramuscular injection.